Study record

Mitochondrial-derived peptides in cardiovascular disease: Novel insights and therapeutic opportunities

Li Y, Li Z, Ren Y et al. · J Adv Res · 2024

ReviewSeveralEvidence tier R

What this study reported

Reviewed the biogenesis, types and reported functions of mitochondria-derived peptides including MOTS-c, and summarised reports that their levels are lower with ageing and in cardiovascular disease.

Limitations

Narrative review with no systematic search or quality appraisal; the summarised evidence is largely preclinical and the review does not weigh study quality.

Study record

Annotated fields for this study
Study modelReview
Substance studiedSeveralMore than one of these is central to the paper (common for reviews).
SpeciesNot reported
System studiedNarrative review of mitochondria-derived peptides in cardiovascular disease
PopulationNot reported
DesignNarrative review
Sample size as reportedNot reported
Control groupNot reported
Route (data field only)Not reported
Endpoints measuredmitochondria-derived peptide biogenesis and types; apoptosis; inflammation; oxidative stress; reported diagnostic and treatment research in cardiovascular disease
Pathways measuredApoptosis · Inflammation · Oxidative stress
Research areasCardiovascular · Mitochondrial biology
Evidence tierR — Review (context, not evidence)
Publication typesJournal Article, Review, Research Support, Non-U.S. Gov't

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Direct
Model applicability
n/a
Sample size
n/a
Controls
n/a
Outcome validity
n/a
Support for its own conclusion
Moderate

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.